早产儿采用低预防性血小板输注阈值均获益
研究基于PlaNeT-2试验数据,纳入653例早产儿,用多因素logistic回归模型预测基线大出血和/或死亡风险,并按风险四分位分组比较25×10^9/L与50×10^9/L预防性输注阈值的绝对风险差异。结果显示,25×10^9/L阈值在所有风险组均与绝对风险降低相关,降幅从最低风险组的4.9%到最高风险组的12.3%。
要点
- 25×10^9/L预防性血小板输注阈值在全部风险组均与绝对风险降低相关。
- 绝对风险降低幅度从最低风险组的4.9%到最高风险组的12.3%。
- 所有早产儿均可采用25×10^9/L预防性血小板输注阈值,无需考虑预测基线风险。
核心结论
- 25×10^9/L预防性血小板输注阈值可在所有早产儿中采用, irrespective of predicted baseline outcome risk。
研究设计与样本
- 基于PlaNeT-2试验数据,纳入全部653例早产儿,建立多因素logistic回归模型预测基线大出血和/或死亡风险。
- 按预测基线风险将患儿排序并分为4个风险四分位组,比较50×10^9/L与25×10^9/L阈值组的绝对风险差异。
主要发现
- 共146例早产儿死亡或发生大出血。
- 模型内部验证C-statistic为0.63(95%CI 0.58-0.68)。
- 25×10^9/L阈值在所有风险组均与绝对风险降低相关,从最低风险组的4.9%到最高风险组的12.3%。
关键数值与推荐
- 预防性血小板输注阈值25×10^9/L vs 50×10^9/L。
- 绝对风险降低:最低风险组4.9%,最高风险组12.3%。
临床怎么用
- 早产儿预防性血小板输注可采用25×10^9/L阈值,无需根据预测基线风险选择更高阈值。
局限性
- 基线风险预测模型的内部验证C-statistic为0.63(95%CI 0.58-0.68),预测准确性有待提高。
- 未来研究需改进基线风险模型的预测准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Platelets for Neonatal Thrombocytopenia (PlaNeT-2) trial reported an unexpected overall benefit of a prophylactic platelet transfusion threshold of 25 × 109/L compared with 50 × 109/L for major bleeding and/or mortality in preterm neonates (7% absolute-risk reduction). However, some neonates in the trial may have experienced little benefit or even harm from the 25 × 109/L threshold. We wanted to assess this heterogeneity of treatment effect in the PlaNet-2 trial, to investigate whether all preterm neonates benefit from the low threshold. We developed a multivariate logistic regression model in the PlaNet-2 data to predict baseline risk of major bleeding and/or mortality for all 653 neonates. We then ranked the neonates based on their predicted baseline risk and categorized them into 4 risk quartiles. Within these quartiles, we assessed absolute-risk difference between the 50 × 109/L- and 25 × 109/L-threshold groups. A total of 146 neonates died or developed major bleeding. The internally validated C-statistic of the model was 0.63 (95% confidence interval, 0.58-0.68). The 25 × 109/L threshold was associated with absolute-risk reduction in all risk groups, varying from 4.9% in the lowest risk group to 12.3% in the highest risk group. These results suggest that a 25 × 109/L prophylactic platelet count threshold can be adopted in all preterm neonates, irrespective of predicted baseline outcome risk. Future studies are needed to improve the predictive accuracy of the baseline risk model. This trial was registered at www.isrctn.com as #ISRCTN87736839.
引用
- Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D, et al. Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood. 2019. PMID: 31697817. doi:10.1182/blood.2019000899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。